ArticleScientific reports2025
OVision A raspberry Pi powered portable low cost medical device framework for cancer diagnosis.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer remains a major global health challenge, with significant disparities in access to advanced diagnostic and prognostic technologies, especially in resource-constrained settings. Existing medical treatments and devices for cancer diagnosis are often prohibitively expensive, limiting their reach and impact. Pathologists' scarcity exacerbates cancer diagnosis accuracy, elevating mortality risks. To address these critical issues, this study presents OVision - a low cost, deep learning-powered framework developed to assist in histopathological diagnosis. The key objective is to leverage the portable, low-power computing Raspberry Pi. By designing standalone devices that eliminate the need for internet connectivity and high-end infrastructure, we can dramatically reduce costs while maintaining accuracy. As a proof of concept, the study demonstrated the viability of this framework through a compact, self-contained device capable of accurately detecting ovarian cancer subtypes with 95% accuracy, on par with traditional methods, while costing a small fraction of the price. This portable, off-grid solution has immense potential to improve access to precision cancer diagnostics, especially in underserved regions of the world that lack the resources to deploy expensive, infrastructure-heavy medical technologies. In addition, by classifying each tile, the tool can provide percentages of each histologic subtype detected within the slide. This capability enhances the diagnostic precision, offering a detailed overview of the heterogeneity within each tissue sample, helps in understanding the complexity of histologic subtypes and tailoring personalized treatment plans. In conclusion, this work proposes a transformative model for developing affordable, accessible medical devices that can bring advanced healthcare benefits to all, laying the foundation for a more equitable, inclusive future of precision medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.